| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ferenc Zádor, Gábor Nagy-Grócz, Gabriella Kekesi, Szabolcs Dvorácskó, Edina Szűcs, Csaba Tömböly, Gyongyi Horvath, Sándor Benyhe, László Vécse. Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions. Molecules (Basel, Switzerland). vol 24. issue 20. 2020-02-20. PMID:31619006. |
kynurenines and the endocannabinoid system in schizophrenia: common points and potential interactions. |
2020-02-20 |
2023-08-13 |
Not clear |
| Mohamed A Sherif, Jose A Cortes-Briones, Mohini Ranganathan, Patrick D Skosni. Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis. The European journal of neuroscience. vol 48. issue 8. 2019-11-14. PMID:29247465. |
preclinical and clinical data suggest that the cannabinoid and glutamatergic systems are implicated in the pathophysiology of schizophrenia (sz), the prototypical psychotic disorder. |
2019-11-14 |
2023-08-13 |
Not clear |
| F Markus Leweke, Juliane K Mueller, Bettina Lange, Stefan Fritze, Cristina E Topor, Dagmar Koethe, Cathrin Rohlede. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. CNS drugs. vol 32. issue 7. 2019-10-10. PMID:30022465. |
role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention. |
2019-10-10 |
2023-08-13 |
Not clear |
| F Markus Leweke, Juliane K Mueller, Bettina Lange, Stefan Fritze, Cristina E Topor, Dagmar Koethe, Cathrin Rohlede. Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. CNS drugs. vol 32. issue 7. 2019-10-10. PMID:30022465. |
since its discovery, multiple clinical and preclinical studies have linked the endocannabinoid system to schizophrenia. |
2019-10-10 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
proteomics and lipidomics in the elucidation of endocannabinoid signaling in healthy and schizophrenia brains. |
2019-09-12 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
additionally, the endocannabinoid signaling network with other non-cannabinoid targets, and the effects of phytocannabinoids increase the complexity to understand their role in schizophrenia and homeostasis conditions. |
2019-09-12 |
2023-08-13 |
Not clear |
| Gabriela Seabra, Ana Caroline B Falvella, Paul C Guest, Daniel Martins-de-Souza, Valéria de Almeid. Proteomics and Lipidomics in the Elucidation of Endocannabinoid Signaling in Healthy and Schizophrenia Brains. Proteomics. vol 18. issue 18. 2019-09-12. PMID:30070429. |
herein, the authors review proteomic and lipidomic studies that have been used for analysis of the endocannabinoid system in healthy and schizophrenia function. |
2019-09-12 |
2023-08-13 |
Not clear |
| Maya R Jacobson, Jeremy J Watts, Isabelle Boileau, Junchao Tong, Romina Mizrah. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 29. issue 3. 2019-08-26. PMID:30635160. |
the most well established finding is the down-regulation of cannabinoid cb1 receptors (cb1r) after chronic and recent cannabis exposure, but it remains uncertain whether this effect is present in cannabis users with schizophrenia. |
2019-08-26 |
2023-08-13 |
Not clear |
| Inés Ibarra-Lecue, Fuencisla Pilar-Cuéllar, Carolina Muguruza, Eva Florensa-Zanuy, Álvaro Díaz, Leyre Urigüen, Elena Castro, Angel Pazos, Luis F Callad. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochemical pharmacology. vol 157. 2019-07-08. PMID:30026022. |
the present review will summarize the latest information on the role of the endocannabinoid system in psychiatric disorders, specifically depression, anxiety, and schizophrenia. |
2019-07-08 |
2023-08-13 |
human |
| Zhiling Guo, Yiu Chung Tse, Ying Zhang, Qiang Sun, Haley A Vecchiarelli, Robert Aukema, Matthew N Hill, Tak Pan Wong, Patricia Boks. Prenatal immune activation potentiates endocannabinoid-related plasticity of inhibitory synapses in the hippocampus of adolescent rat offspring. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 28. issue 12. 2019-06-12. PMID:30257799. |
the endocannabinoid (ecb) system has been implicated in the pathophysiology of schizophrenia while models of cortical dysfunction postulate an imbalance between neuronal excitation and inhibition in the disorder. |
2019-06-12 |
2023-08-13 |
rat |
| Felipe V Gomes, Jessica R Edelson, David W Volk, Anthony A Grac. Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia. Schizophrenia research. vol 201. 2019-05-20. PMID:29705007. |
altered brain cannabinoid 1 receptor mrna expression across postnatal development in the mam model of schizophrenia. |
2019-05-20 |
2023-08-13 |
human |
| Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K Mueller, Andreas Meyer-Lindenberg, E Fuller Torrey, Daniele Piomelli, F Markus Lewek. Familial abnormalities of endocannabinoid signaling in schizophrenia. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 20. issue 2. 2019-05-14. PMID:29521179. |
familial abnormalities of endocannabinoid signaling in schizophrenia. |
2019-05-14 |
2023-08-13 |
Not clear |
| Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K Mueller, Andreas Meyer-Lindenberg, E Fuller Torrey, Daniele Piomelli, F Markus Lewek. Familial abnormalities of endocannabinoid signaling in schizophrenia. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 20. issue 2. 2019-05-14. PMID:29521179. |
epidemiological and experimental evidence suggests that the endocannabinoid system plays a pathophysiological role in schizophrenia. |
2019-05-14 |
2023-08-13 |
Not clear |
| Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K Mueller, Andreas Meyer-Lindenberg, E Fuller Torrey, Daniele Piomelli, F Markus Lewek. Familial abnormalities of endocannabinoid signaling in schizophrenia. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 20. issue 2. 2019-05-14. PMID:29521179. |
this is reflected by elevated cerebrospinal levels of the endocannabinoid anandamide in schizophrenia and its initial prodromal states. |
2019-05-14 |
2023-08-13 |
Not clear |
| David D Aguilar, Andrea Giuffrida, Daniel J Lodg. Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility. The international journal of neuropsychopharmacology. vol 21. issue 4. 2019-04-29. PMID:29329382. |
adolescent synthetic cannabinoid exposure produces enduring changes in dopamine neuron activity in a rodent model of schizophrenia susceptibility. |
2019-04-29 |
2023-08-13 |
Not clear |
| Pankaj Pandey, Narayan D Chaurasiya, Babu L Tekwani, Robert J Doerkse. Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. Biochemical pharmacology. vol 155. 2019-04-04. PMID:29958841. |
the endocannabinoid system plays an important role in the pathophysiology of various neurological disorders, such as anxiety, depression, neurodegenerative diseases, and schizophrenia; however, little information is available on the coupling of the endocannabinoid system with the monoaminergic systems in the brain. |
2019-04-04 |
2023-08-13 |
human |
| Valéria de Almeida, Daniel Martins-de-Souz. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European archives of psychiatry and clinical neuroscience. vol 268. issue 7. 2018-12-19. PMID:29392440. |
cannabinoids and glial cells: possible mechanism to understand schizophrenia. |
2018-12-19 |
2023-08-13 |
Not clear |
| Valéria de Almeida, Daniel Martins-de-Souz. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European archives of psychiatry and clinical neuroscience. vol 268. issue 7. 2018-12-19. PMID:29392440. |
clinical and neurobiological findings have reported the involvement of endocannabinoid signaling in the pathophysiology of schizophrenia. |
2018-12-19 |
2023-08-13 |
Not clear |
| Valéria de Almeida, Daniel Martins-de-Souz. Cannabinoids and glial cells: possible mechanism to understand schizophrenia. European archives of psychiatry and clinical neuroscience. vol 268. issue 7. 2018-12-19. PMID:29392440. |
in this regard, glial cells express cannabinoid receptors and synthesize endocannabinoids, and cannabinoid drugs affect some functions of these cells that can be implicated in schizophrenia pathobiology. |
2018-12-19 |
2023-08-13 |
Not clear |
| Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi, Franco Dosi. Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules (Basel, Switzerland). vol 23. issue 10. 2018-12-12. PMID:30262735. |
there is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. |
2018-12-12 |
2023-08-13 |
Not clear |